Learn more about the
symptoms and diagnosis
of Parkinson's disease
Click here
MIRAPEX added nearly
2 hours of "on" time
Learn more

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

In early Parkinson's disease, MIRAPEX significantly improves activities of daily living and motor scores

At 4 years, fewer than half of patients on MIRAPEX plus levodopa experienced dyskinesia, compared with patients on levodopa alone1

Mirapex helped improve ADL and UPDRA by delaying major motor complications

The Parkinson Study Group. JAMA, 2000; Archives of Neurology, 2004.
Multicenter, parallel-group, double-blind, randomized, controlled trial in 301 patients with early Parkinson's disease (Hoehn and Yahr stages I-III). Objective: to compare initial treatment with MIRAPEX vs levodopa with respect to the development of dopaminergic motor complications. Dosing: (2 year): subjects were escalated initially to a daily dose of MIRAPEX 1.5 mg or levodopa 75/300 mg; (4 year): the maintenance dose of MIRAPEX was maintained throughout the trial; supplemental levodopa was permitted if needed. Patients were titrated to a maximum dose of MIRAPEX 4.5 mg or levodopa 600 mg. Primary outcome variables were time to the first occurrence of dopaminergic complications: wearing-off, dyskinesia, or "on"-"off " fluctuations. Secondary outcome variables included changes in UPDRS (Unified Parkinson's Disease Rating Scale) scores. Conclusion: initial treatment with MIRAPEX resulted in fewer incidences of dyskinesia and wearing-off compared with levodopa.

  • After 5 years of levodopa therapy, approximately 60% of patients develop troublesome motor complications13
    • - Patients less than 60 years of age are prone to developing these complications sooner13
 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.